Table 4 Order of relative importance

(1) Route of administration (TA); (2) combination therapy (O); (3) frequency of administration (TA); (4) possible side effects (R); and (5) time till onset drug effect (B)

(1) Cost per month (C); (2) general adverse events (R); (3) frequency of administration (TA); (4) efficacy patient global assessment (B); (5) route of administration (TA); (6) local adverse events (R); and (7) serious infection (R)

(1) Treatment effectiveness (B); (2) severe side effects (R); (3) psychological side effects (R); (4) route of administration (TA); (5) frequency of administration (TA); (6) side effects changing appearance (R); and (7) mild side effects (R)

White participants:

(1) Likelihood of remission (B); (2) likelihood of arresting radiographic progression (B); (3) likelihood of symptoms improving (B); (4) risk of cancer (R); (5) risk of lung injury (R); (6) route of administration (TA); (7) risk of injection reaction (R); (8) risk of neurologic disease or heart failure (R); (9) reversible adverse events (R.); and (10) risk of tuberculosis (R)

(1) Time with optimal quality of life (B); (2) mode of administration (TA); (3) onset of treatment action (B); (4) probability of severe adverse events (R); (5) monthly co-pay (C); (6) substantial Improvement in symptoms (B); and (7) Probability of mild adverse events (R)

(1) Less common, but serious AE (R; separate attributes: kidney damage/liver damage/cancer/lung damage); (2) common, but reversible AE (R; separate attributes: alopecia/oral ulcers/nausea/injection reaction/rash/diarrhoea); (3) route and frequency of administration (TA); (4) drug onset (B); (5) monthly co-pay (C); (6) physician experience (O); (7) chance of benefit (B) and (8) no new bone damage at year1 (B)

No order of relative importance available: Decreased joint pain and swelling (B); ability to get around and participate in social or leisure activities outside of the house (B); slowing or stopping joint damage seen on x-rays (B); ability to work (B); risk of injection/infusion reaction (R); risk of infection (R); risk of TB (R) and risk of neurological disease (R)

(1) Cost (C); (2) bothersome side effects (R); (3) very rare side effects (R); (4) onset of action (B); (5) serious infection (R); (6) route of administration (TA); and (7) amount of information available (O)

(1) Major symptom improvement by 6 month (B); (2) reduction in chance of serious joint damage (B); (4) route and frequency of administration (TA); (5) small risk of serious infection/possible increased risk of cancer (R); (6) stopping due to side effect by 6 months (R); (7) lung/liver reaction (O); (8) alcohol restriction (O); and (9) eye screening (O)

Reported for RA patients, AS patients and PsA patients combined^b:

(1) Improvement in physical function (B); (2) reduction in pain (B); (3) reduction in number of swollen joints (B); (4) route of administration (TA); (5) risk of cancer (R); (6) monthly co-pay (C); (7) frequency of administration (TA); (8) abnormal lab results (R); and (9) risk of serious infection (R)

(1) Route of administration (TA); (2) frequency of administration (TA); (3) serious adverse events (R); (4) monthly co-pay (C); (5) medication burden (O); (6) joint pain reduction (B); and (7) daily task improvement (B)

(1) Pain relief and improvement in functional capacity (B); (2) risk of adverse events (R); (3) route of administration (TA); and (4) duration of effect (B)

Cheap talk sample only: (1) Monthly co-pay (C); (2) chance the medication works well (B); (3) route of administration and frequency (TA); (4) serious infection (R); (5) onset of effect (B); and (6) duration of injection site irritation (R)

(1) Immediate serious reaction (R); (2) medication working well (B); (3) frequency of administration (TA); (4) time for infusion (TA); (5) immediate mild reaction (R); and (6) route of administration (TA)

(1) Frequency of reactions at the site of drug administration (R); (2) additional costs through taxes (C); (3) manner, helpfulness, efficiency and courtesy of health personnel (O); (4) generalised undesired reactions or allergic reactions (R); (5) Route and place of administration (T); and (6) frequency of administration (TA)

WTP (1000 DKK), survey 1 only: (1) tiredness (B); (2) slightly higher risk of a minor infection (R); (3) pain level (B); (4) swollen joints (B); (5) morning stiffness (B); and (6) co-pay (C)

No order of relative importance available: Route of administration (A); frequency of administration (A); onset of action (B); risk of cancer (R); risk of liver injury (R); risk of serious infections (R); and chance of efficacy (B)

(1) How many people receiving the drug are likely to feel better within 6 months (B); (2) route and duration of administration (TA); (3) life-expectancy (B)^c; (4) minor side effects (R); (5) frequency of administration (TA); and (6) serious side effect: number of people have to stop medication (R)

(1) How many people receiving the drug are likely to feel better within 6 months (B); (2) confidence in risk/benefit estimates (O); (3) serious side effect: number of people have to stop medication (R); (4) route of administration (TA); and (6) frequency of administration (TA)

(1) Reduction in RA risk (B); (2) risk of SAE (R); (3) mild AE (R); and (4) mode of administration (TA)

(1) Route of administration (TA); (2) reduction in RA risk (B); (3) health care professional preference (O); (4) chance of side effects (R); and (5) certainty in evidence (O)

Patients and FDR sample combined: (1) Health care professional preference (O); (2) chance of side effects (R); (3) reduction in RA risk (B); (4) route of administration (TA); and (5) certainty in evidence (O)